In nasopharyngeal carcinoma (NPC), cancer-associated fibroblast-derived fibroblast growth factor 5 (FGF5) activates fibroblast growth factor receptor 2 (FGFR2)–Nrf2 signaling, thereby dampening cisplatin-induced ferroptosis and promoting chemoresistance [30]. Here, FGFR2 is linked to nasopharyngeal carcinoma.